1. Home
  2. CRDF vs MACI Comparison

CRDF vs MACI Comparison

Compare CRDF & MACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRDF
  • MACI
  • Stock Information
  • Founded
  • CRDF 1999
  • MACI 2024
  • Country
  • CRDF United States
  • MACI United States
  • Employees
  • CRDF N/A
  • MACI N/A
  • Industry
  • CRDF Biotechnology: Biological Products (No Diagnostic Substances)
  • MACI
  • Sector
  • CRDF Health Care
  • MACI
  • Exchange
  • CRDF Nasdaq
  • MACI NYSE
  • Market Cap
  • CRDF 196.2M
  • MACI 221.6M
  • IPO Year
  • CRDF N/A
  • MACI 2024
  • Fundamental
  • Price
  • CRDF $2.66
  • MACI $10.32
  • Analyst Decision
  • CRDF Strong Buy
  • MACI
  • Analyst Count
  • CRDF 4
  • MACI 0
  • Target Price
  • CRDF $12.25
  • MACI N/A
  • AVG Volume (30 Days)
  • CRDF 1.1M
  • MACI 9.3K
  • Earning Date
  • CRDF 05-08-2025
  • MACI 01-01-0001
  • Dividend Yield
  • CRDF N/A
  • MACI N/A
  • EPS Growth
  • CRDF N/A
  • MACI N/A
  • EPS
  • CRDF N/A
  • MACI N/A
  • Revenue
  • CRDF $587,000.00
  • MACI N/A
  • Revenue This Year
  • CRDF N/A
  • MACI N/A
  • Revenue Next Year
  • CRDF N/A
  • MACI N/A
  • P/E Ratio
  • CRDF N/A
  • MACI $44.17
  • Revenue Growth
  • CRDF N/A
  • MACI N/A
  • 52 Week Low
  • CRDF $2.01
  • MACI $9.95
  • 52 Week High
  • CRDF $5.64
  • MACI $10.35
  • Technical
  • Relative Strength Index (RSI)
  • CRDF 42.40
  • MACI N/A
  • Support Level
  • CRDF $2.42
  • MACI N/A
  • Resistance Level
  • CRDF $2.87
  • MACI N/A
  • Average True Range (ATR)
  • CRDF 0.19
  • MACI 0.00
  • MACD
  • CRDF 0.01
  • MACI 0.00
  • Stochastic Oscillator
  • CRDF 27.91
  • MACI 0.00

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

About MACI MELAR ACQUISITION CORP. I

Melar Acquisition Corp I is a blank check company.

Share on Social Networks: